Arkea Bio Corp.
StreetZero Signal 69
About Arkea Bio Corp.
ArkeaBio is a Boston-based agricultural biotechnology company developing a vaccine-based solution to reduce enteric methane emissions from cattle. It targets the global dairy and beef industries with a scalable tool to neutralize methanogenic archaea in the rumen. The company operates with 21-50 employees and maintains its headquarters in Charlestown, MA.
LATEST FUNDINGPrivate Placement
$15.0M
Announced 2026-10-09
TOTAL RAISED$45.5M
IN THE NEWS
- 🔗 ArkeaBio - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Arkea Bio: Funding, Team & Investors | Startup Intros
- 🔗 ArkeaBio Names Frank Wooten CEO, Closes A1 Funding
- 🔗 ArkeaBio™ Raises $26.5M to Reduce Greenhouse Gas Emissions with Methane Vaccine
- 🔗 ArkeaBio 2026 Company Profile: Valuation, Funding & Investors | PitchBook
EMPLOYEES21-50
FOUNDED2022
HQCharlestown, MA, United States
Industry
Other Technology
Tags
AgriTechBiotechClimateTechVaccine
Key highlights
- Closed $26.5M Series A in 2024 to advance methane vaccine development.
- Appointed Frank Wooten as CEO and Dr. Zach Serber as CTO.
- Reduced headcount by approximately one-third while progressing toward commercialization.
- Backed by climate-focused investors including Breakthrough Energy Ventures and The Grantham Foundation.
Ask StreetZero about Arkea Bio Corp.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account